Keywords
Chronic kidney disease
Monoclonal proteins
Renal failure
Overall survival
Glomerular filtration rate
How to Cite
Abstract
Background: Multiple myeloma (MM) is a malignant plasma cell disorder characterized by the accumulation of abnormal monoclonal plasma cells in the bone marrow. Chronic kidney disease (CKD) is a common complication in patients with multiple myeloma.
Objective: To assess the survival rates among patients with multiple myeloma with any stage of chronic kidney disease treated at the Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México.
Materials and methods: Patients with multiple myeloma treated at Clinica Ruiz, Puebla, Mexico, over a 40-year period (1983 to 2023) were analyzed. Age, gender, laboratory data, and treatment features were reviewed. Patients were grouped according to their stage of CKD. The key endpoint was overall survival (OS). Differences in survival were assessed using Kaplan-Meier curves, while changes in glomerular filtration rate (GFR) were evaluated using Student's t-test.
Results: A total of 124 patients were included. Renal damage (stages G2-G5) was present in 68% of patients; the patient distribution was determined as G1 (n=39), G2 (n=40), G3 (n=30), G4 (n=9), and G5 (n=6). Overall survival significantly differed between stage G1 and stages G2-G5 (p=0.0412). The median overall survival was not reached for G1, 85.37 months for G2, and 79.8 months for G3. A T-test of glomerular filtration rate before and after treatment showed no significant difference (p=0.3466).
Conclusion: Chronic kidney disease is associated with reduced survival in patients with multiple myeloma at any stage.
References
Malard F, Neri P, Bahlis N, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10(1):45. https://doi.org/10.1038/s41572-024-00529-7
Albagoush SA, Shumway C, Azevedo AM. Multiple myeloma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962–2972. https://doi.org/10.1182/blood-2007-10-078022
Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43(6):676–681. https://doi.org/10.1053/j.seminoncol.2016.11.004
Smith CJ, Ambs S, Landgren O. Biological determinants of health disparities in multiple myeloma. Blood Cancer J. 2018;8(9):85. https://doi.org/10.1038/s41408-018-0118-z
Ruiz-Delgado GJ, Gómez Rangel JD. Gamapatía monoclonal de significado indeterminado (GMSI) en mestizos mexicanos. Experiencia de una sola institución. Gac Med Mex. 2004;140(4):375–379.
Wang L, Liu C, Song H, Yuan J, Zha Y, Deng Y. Update on kidney injury caused by multiple myeloma. Ann Hematol. 2024;103:5007-5018. https://doi.org/10.1007/s00277-024-05860-3
Bridoux F, Leung N, Belmouaz M, Nasr SH, Fermand JP, Royal V, et al. Management of acute kidney injury in symptomatic multiple myeloma. Kidney Int. 2021;99(3):570-580. https://doi.org/10.1016/j.kint.2020.11.010
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548. https://doi.org/10.1016/S1470-2045(14)70442-5
Vaidya SR, Aeddula NR. Chronic kidney disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
Murrieta-Álvarez I, Steensma DP, Olivares-Gazca JC, Olivares-Gazca M, León-Peña A, Cantero-Fortiz Y, et al. Treatment of persons with multiple myeloma in underprivileged circumstances: Real-world data from a single institution. Acta Haematol. 2020;143(6):552–558. https://doi.org/10.1159/000505606
Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res. 2010;1(4):274–278. https://doi.org/10.4103/0974-7788.76794
Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Eur J Haematol. 2001;65(3):175–181. https://doi.org/10.1034/j.1600-0609.2000.90221.x
Uttervall K, Duru AD, Lund J, Liwing J, Gahrton G, Holmberg E, et al. The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment. PloS One. 2014;9(7):e101819. https://doi.org/10.1371/journal.pone.0101819
Courant M, Orazio S, Monnereau A, Preterre J, Combe C, Rigothier C. Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: A population-based registry. Nephrol Dial Transplant. 2021;36(3):482–490. https://doi.org/10.1093/ndt/gfz211
Lazana I, Floro L, Christmas T, Shah S, Bramham K, Cuthill K, et al. Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: A safe and effective option. Bone Marrow Transplant. 2022;57(6):959–965. https://doi.org/10.1038/s41409-022-01657-y
Kaygusuz I, Toptas T, Aydin F, Uzay A, Firatli-Tuglular T, Bayik M. Bortezomib in patients with renal impairment. Hematology. 2011;16(4):200–208. https://doi.org/10.1179/102453311X13025568941880
Ludwig H, Drach J, Graf H, Lang A, Meran JG. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica. 2007;92(10):1411–1414. https://doi.org/10.3324/haematol.11463
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.